The aryl hydrocarbon receptor (AHR) is critically involved in several physiologic processes, including cancer progression and multiple immune system activities. We, and others, have hypothesized that AHR modulators represent an important new class of targeted therapeutics. Here, ligand shape-based virtual modeling techniques were used to identify novel AHR ligands on the basis of previously identified chemotypes. Four structurally unique compounds were identified. One lead compound, 2-((2-(5-bromofuran-2-yl)-4-oxo-4H-chromen-3-yl)oxy) acetamide (CB7993113), was further tested for its ability to block three AHR-dependent biologic activities: triple-negative breast cancer cell invasion or migration in vitro and AHR ligand-induced bone marrow toxicity in vivo. CB7993113 directly bound both murine and human AHR and inhibited polycyclic aromatic hydrocarbon (PAH)-and TCDD-induced reporter activity by 75% and 90% respectively. A novel homology model, comprehensive agonist and inhibitor titration experiments, and AHR localization studies were consistent with competitive antagonism and blockade of nuclear translocation as the primary mechanism of action. CB7993113 (IC 50 3.3 Â 10 27 M) effectively reduced invasion of human breast cancer cells in three-dimensional cultures and blocked tumor cell migration in two-dimensional cultures without significantly affecting cell viability or proliferation. Finally, CB7993113 effectively inhibited the bone marrow ablative effects of 7,12-dimethylbenz[a]anthracene in vivo, demonstrating drug absorption and tissue distribution leading to pharmacological efficacy. These experiments suggest that AHR antagonists such as CB7993113 may represent a new class of targeted therapeutics for immunomodulation and/or cancer therapy.
Introduction
The aryl hydrocarbon receptor (AHR) field has undergone a dramatic paradigm shift in the last few years. Historically, the evolutionarily conserved AHR was studied for its ability, upon activation by environmental ligands, to regulate genes encoding a battery of cytochrome P450 enzymes that metabolize at least some of those ligands into metabolic intermediates, some of which are toxic (Hankinson et al., 1991; Nebert et al., 1991) . Similarly, studies published over the last 20-30 years demonstrate the role of the AHR in the initiation of environmental chemical-induced cancers, to a large extent through P450-dependent generation of mutagenic intermediates. Consequently, studies on the effects of AHR activation, primarily by anthropogenic ligands, most frequently involved tissue toxicity or the initiation of malignancy.
However, several landmark studies now demonstrate that the AHR plays a critical role in several physiologic processes in the absence of environmental chemicals. These studies show that the AHR, presumably activated by endogenous ligands, plays a critical role in the manifestation or control of tissue inflammation and autoimmunity through enforcement of inflammatory cytokine production by monocytes (Wu et al., 2011) and synoviocytes (Lahoti et al., 2013) , the production of inflammatory Th 17 and immunosuppressive regulatory T cells (Veldhoen et al., 2008) , and the regulation of apoptosis (Caruso et al., 2004 (Caruso et al., , 2006 . Indeed, the recent demonstration that AHR activation drives production of erythroid cells from pluripotent stem cell precursors (Smith et al., 2013) , is required for development of gut-associated T cells (Kiss et al., 2011; Lee et al., 2012) , and influences the differentiation of human hematopoietic stem cells (Boitano et al., 2010) suggests a critical role of the AHR in hematopoiesis in general.
Furthermore, several studies now implicate the AHR in cancer progression in the absence of environmental ligands. For example, AHR activated by an endogenous tryptophanderived metabolite increases human glioblastoma cell survival and migration (Opitz et al., 2011) . The AHR-repressor (AHRR) protein acts as a tumor suppressor gene in several human cancers (Zudaire et al., 2008) . AHR expression and "constitutive" (endogenous ligand-driven) activity in breast cancer cells correlate with tumor aggressiveness (Schlezinger et al., 2006; Yang et al., 2008) and control expression of genes associated with tumor invasion (Yang et al., 2005) . Surveys of cytochrome P450 protein expression identified the AHR gene targets CYP1A1, CYP1A2, and CYP1B1 in most types of primary human tumor samples examined, including solid and hematologic malignancies (Maecker et al., 2003) , and found that expression of the AHR target gene CYP2S1 inversely correlates with patient survival (Murray GI et al., 2010) . Finally, ectopic AHR expression in nonmalignant human mammary epithelial cells induces an epithelial-to-mesenchymal transition and a .50% increase in cell growth rates (Brooks and Eltom, 2011) . Together, these studies strongly support the hypothesis that the AHR plays an important role in the later, more aggressive stages of cancer, even in the absence of environmental ligands.
Given the involvement of the AHR in blood cell development and multiple immune system phenomena, and its postulated role in cancer progression, we and others have hypothesized that AHR modulators, either agonists or antagonists, may represent an important new class of targeted therapeutics (Schlezinger et al., 2006; Zhang et al., 2009) . We postulate that AHR antagonists in particular may be important for treatment of high AHR expressing, triple-negative breast cancers (TNBCs), malignancies which are particularly resistant to current chemotherapeutics and nonresponsive to hormone receptor-targeted therapeutics.
The identification of novel, potent AHR modulators has been hampered by the limited amount of data on the three-dimensional structure of the AHR protein, and specifically the structure of its ligand-binding domain (LBD) . In its stead, researchers have developed structural homology models on the basis of ligandbinding domains of familial proteins (Motto et al., 2011; Xing et al., 2012) . Although recent advancements in AHR-LBD models have improved our understanding of the requirements for AHR binding, the abilities of these programs to predict AHR ligands is only beginning to be realized.
Here, we used ligand shape-based virtual screening techniques to rapidly screen libraries of over 1 million commercially available small molecule compounds for potential AHR ligands. The focused library identified by this analysis was tested in a high-throughput in vitro bioassay for AHR-antagonist activity.
Lead compounds chosen from the in vitro screening assays were characterized for their ability to directly bind the AHR and to block AHR nuclear translocation and transcriptional activity. One lead compound, CB7993113, was examined for its probable binding conformation to the AHR PAS-B domain. Finally, CB7993113 was tested for its ability to block three AHRdependent biologic activities, triple-negative breast cancer cell invasion and migration in vitro, and AHR ligand-induced bone marrow toxicity in vivo.
Materials and Methods

Chemical Reagents
Commercial chemical libraries of test compounds were acquired from ChemBridge Corporation (San Diego, CA) and Enamine (Kiev, Ukraine). Dimethyl sulfoxide (DMSO), b-naphthoflavone (b-NF), 7,12-dimethylbenz [a] anthracene (DMBA), TCDD, and other chemical reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated. CB7993113 and CH223191 were synthesized as below. All compounds submitted for biologic testing were deemed at least .98% pure by HPLC (with UV and mass spectral detection) and 1 H NMR. Chemical Synthesis of CB7993113. 1-(2-Hydroxyphenyl)ethanone (1.720 g, 14.29 mmol) and 5-bromofuran-2-carbaldehyde (2.5 g, 14.29 mmol) were dissolved in a round-bottom flask in 10 ml of ethanol. A solution of 17 M NaOH (1.5 ml) in water was then added under vigorous stirring. Precipitate formed under addition of base, and a thick paste was formed. The mixture was stirred for 24 hours at room temperature. Ethanol (50 ml) was added with 0.5 ml of 2.5 M NaOH. The mixture was cooled to 15°C and hydrogen peroxide was added (35% in water, 6.25 ml, 71.4 mmol). After 4 hours, dilute sulfuric acid was added to neutralize to pH 7.0, and the reaction was poured into 250 ml of water and stirred for 2 hours. The solid material was collected by filtration and dried under vacuum to give a yellow solid (1.01 g, 23% yield). 1 H NMR (399 MHz, DMSO-d 6 ) d ppm 4.60 (s, 2 H) 6.98 (d, J 5 3.66 Hz, 1 H) 7.39 (br s, 1 H) 7.50 (t, J 5 7.33 Hz, 1 H) 7.67-7.78 (m, 3 H) 7.81 (d, J 5 7.33 Hz, 1 H) 8.08 (d, J 5 8.06 Hz, 1 H).) A mixture of 2-(5-bromofuran-2-yl)-3-hydroxy-4H-chromen-4-one thus obtained (910 mg, 2.96 mmol), 2-bromoacetamide (409 mg, 2.96 mmol), potassium carbonate (1229 mg, 8.89 mmol), and dimethylformamide (30 ml) was stirred for 6 hours at 80°C. The solution was cooled and extracted with ethyl acetate. The combined organic layers were washed with water, dried with sodium sulfate, filtered and concentrated. Toluene was added and evaporated repeatedly until dry crystals of crude product were formed. The resulting material was purified by column chromatography, first eluting impurities with 100% ethyl acetate, followed by 10% methanol in methylene chloride to provide CB7993113 as a yellow solid (900 mg, 83% yield). Fig. S1 ). A solution containing 4-amino-29,3-dimethylazobenzene (602 mg, 2.67 mM), 1-methyl-1H-pyrazole-5-carboxylic acid (372 mg, 2.95 mmol,), N,N-diisopropylethyl amine (1.4 ml, 8.04 mmol), and bromotripyrrolidinophosphonium hexafluorophosphate (1.857 g, 3.98 mmol, 1.5 Eq) in 10 ml of 1,2-dichloroethane was heated via microwave irradiation in two equal batches at 120°C for 22 minutes. The reaction mixture was reduced in vacuo, taken up in ethyl acetate (100 ml), and washed using 5% K 2 HPO 4 (100 ml), saturated NaHCO 3 (100 ml), and brine (100 ml). The isolated organic phase was dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure to give a dark brown solid. The residue was purified twice by rapidly stirring in the minimal amount of warm CH 2 Cl 2 and adding hexanes to precipitate the title compound (681 mg, 76%) as an amorphous tan solid. 157.9, 150.7, 149.9, 138.1, 137.8, 137.4, 135.2, 131.3, 130.9, 129.0, 126.4, 124.8, 122.6, 122.2, 115.4, 106.6, 39.5, 17.9, 17.6 
Cell Culture
H1G1.1c3 cells were generously provided by M. S. Denison (University of California, Davis, CA) and maintained as previously described (Nagy et al., 2002) . Cultures of H1G1.1c3 cells were maintained in selective medium consisting of DMEM (Mediatech, Manassas, VA) supplemented with 10% bovine growth serum (HyClone, Logan, UT), 2 mM L-glutamine (Mediatech), 5 mg/ml Plasmocin (InvivoGen, San Diego, CA), and 968 mg/l G-418 sulfate (American Bioanalytical, Natick, MA) in a 37°C humidified incubator in a 5% CO 2 atmosphere. This murine hepatoma cell line contains a stable enhanced green fluorescent protein (EGFP) reporter construct regulated by AHR response elements (AHREs) derived from the CYP1A1 promoter. ER -, PR -, HER -BP1 cells were generously provided by Dr. J. Russo (Fox Chase Cancer Center, Philadelphia, PA). BP1 cells were maintained in phenol red-free DMEM-F/12 medium (Mediatech) containing 5% equine serum (Sigma-Aldrich), 20 ng/ml of human recombinant epidermal growth factor (Life Technologies, Grand Island, NY), 0.5 mg/ml hydrocortisone (Sigma-Aldrich), 2 mM L-glutamine, 100 IU penicillin per 100 mg/ml streptomycin (Mediatech), 10 mg/ml insulin (Sigma-Aldrich), and 5 mg/ml Plasmocin. SUM149 cells were graciously provided by Dr. S. Ethier of Wayne State University (Detroit, MI), who isolated them from a primary inflammatory invasive ductal mammary carcinoma. Cells were maintained in Ham's F-12 medium (Mediatech) containing 5% fetal bovine serum (Sigma-Aldrich), 0.5 mg/ml hydrocortisone, 2 mM L-glutamine, 100 IU penicillin per 100 mg/ml streptomycin, 10 mg/ml insulin, and 5 mg/ml Plasmocin. Hs578T-cell culture was described previously (Yang et al., 2008) . BP1, Hs578T, and SUM149 cells were cultured and assayed at 37°C in a humidified incubator in a 5% CO 2 atmosphere and grown as adherent monolayers at a maximum of 80% confluency.
Molecular Modeling/Predicting AHR Ligands
Commercial compound libraries were used for shape-and electrostaticsbased comparisons. Databases of 445,418 compounds from ChemBridge Corporation (San Diego, CA) and 731,288 compounds from Enamine were used for this scaffold-hopping approach.
The structural file containing a representative flavonoid substructure, 4-oxo-2-phenylchroman-3-yl methylcarbamate, was expanded into a three-dimensional conformer database using OMEGA v.2.2.1 (OpenEye Scientific Software, Santa Fe, NM) (Hawkins and Nicholls, 2012) , allowing an energy window of 8 kcal/mol above ground state, and an msd cutoff of 0.8 Å per the method described in Hawkins et al. (2007) . The two lowest energy conformers were selected and used for subsequent studies.
In a similar way, three-dimensional conformer libraries of the Enamine and ChemBridge collections were generated. No limitation in terms of maximum number of conformers was set. To speed this computation, fragment libraries of each were pregenerated using the program makefragmentlib. The sample flavonoid conformers were compared against the Enamine and ChemBridge conformer databases using Rapid Overlay of Chemical Structures (ROCS; OpenEye). The highest scoring overlaps from ROCS were then subjected to electrostatic overlap comparison using EON (OpenEye). For hit-list ranking, the electrostatic Tanimoto combo (ET) score was used. This is the sum of the shape Tanimoto and the Poisson-Boltzmann electrostatic Tanimoto. The EON hit lists thus generated were merged into two separate structure files (Enamine and ChemBridge) using Pipeline Pilot (Accelrys, San Diego, CA) and each were sorted on the basis of the electrostatic Tanimoto combo score (ET_combo). An order list was thus generated consisting of the top 98 hits from ChemBridge and top 99 hits from Enamine. A summary of the computed properties of this library is presented in Supplemental Table S1 .
High-Throughput AHR Reporter Assay A previously described AHR reporter assay (Nagy et al., 2002) was adapted for high-throughput screening. To each well of a 384-well plate 10 5 H1G1.1c3 cells were added in selective medium and incubated at 37°C for 24 hours. Culture medium was replaced with nonselective medium consisting of MEMa (Life Technologies) supplemented with 10% BGS (HyClone/GE Healthcare Life Sciences, Logan, UT) and 2 mM L-glutamine (Mediatech) prior to application of the test compounds. b-NF was used as a positive control for induction of AHR reporter activity. A b-NF standard curve was generated by applying vehicle (0.1% DMSO) or final concentrations of 10 210 to 10 25 M b-NF to the cultures, with each concentration applied to 24 wells. To assess potential AHR agonist activity, vehicle or 2 ml of each of the 197 chemicals in DMSO diluted 1:10 in media (10 29 to 10 25 M, final concentration) chosen from commercial libraries were applied to triplicate wells. To screen for AHR antagonist activity, cells in 384-well plates were treated with b-NF (10 27 M) and 2 ml vehicle or test compounds at the indicated concentrations. The plates were incubated at 33°C for up to 72 hours. EGFP fluorescence was analyzed at 24, 48, and 72 hours using a fluorometric plate reader (SpectraFluor Plus; Tecan, Männedorf, Switzerland). Percent induction/ inhibition of b-NF-induced AHR activity was calculated by subtracting the background fluorescence of untreated cells from all experimental values and dividing the background-adjusted fluorescence in the sample plus b-NF wells by the background-adjusted fluorescence in the b-NF-alone wells and then multiplying by 100.
Following the final fluorescence reading, the CellTitre-Blue cell viability assay was used to determine toxicity as per the manufacturer's instructions (Promega, Madison, WI). Toxicity was calculated by dividing background-subtracted fluorescent readings of samples by those of untreated cells. Compounds consistently inducing a $10% increase in cell death, relative to baseline levels (generally 2-5%), were excluded from further studies.
Antagonism of TCDD-Induced AHR Activity H1G1.1c3 cells (6 Â 10 5 ) were added to each well of a 96-well plate in selective medium and incubated at 37°C for 24 hours. Culture medium was replaced with nonselective medium prior to application of the test compounds. Eight culture wells were treated with 0.5% DMSO (vehicle) or 10 27 to 5 Â 10 211 M TCDD with or without 0.5% DMSO or 5 Â 10 25 to 10 29 M CB7993113. Plates were incubated at 33°C for 24 hours, and EGFP fluorescence was analyzed using a Synergy 2 Multi-Mode Plate Reader (BioTek Inc., Winooski, VT). For each plate, specific fluorescence was calculated by subtracting the background fluorescence in untreated wells from the fluorescence in vehicle-or compound-treated wells. Percent induction was calculated by dividing by the specific fluorescence in the CB7993113-plus-TCDD wells by the specific fluorescence in cultures treated with vehicle-plus-TCDD for each given TCDD concentration and multiplied by 100. This experiment was repeated six times.
Efficacy and Potency Analyses
To determine 50% inhibitory concentration (IC 50 27 M b-NF (to assay antagonist activity) (six wells/condition). Plates were incubated at 33°C for 24 hours and EGFP fluorescence was analyzed using a Synergy 2 plate reader. Percent AHR induction was calculated as described above. Following the final fluorescence reading, the MTT cell viability assay was used to determine toxicity (Sigma-Aldrich).
Identification of an AHR Antagonist
Briefly, after a 48-hour incubation, 10 ml MTT (5 mg/ml) was added to each well and incubated at 37°C for 4 hours. Formazan crystals were solubilized by the addition of 100 ml/well DMSO and incubation at 37°C for 2 hours. Absorbance at 570 nm was quantified using a Synergy 2 plate reader. Toxicity was calculated by subtracting the average absorbance in the untreated wells from the average absorbance in the experimental wells.
Homology Modeling/Theoretical AHR Binding
The X-ray structure of HIF-2a PAS-B domain cocrystallized with N-(3-chloro-5-fluorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine was chosen as the template for model-building (Scheuermann et al., 2009 ). The structure was downloaded from the Protein Data Bank (PDB) (Berman et al., 2002) . The PDB identifier (PDB ID) of the structure is 4GHI. MODELER (Fiser and Sali, 2003 ) was used to model the human AHR PAS-B domain. Only nonidentical residues and regions around the gaps were optimized. To assure that the binding site would not collapse in the process of model building, CB7993113 was aligned inside the homology model, on the basis of the position of the double ring of the ligand in the template and considering the polarity/hydrophobicity of the environment around it. The ligand-protein complex was then minimized using the CHARMM potential to avoid possible steric clashes (Brooks et al., 1983) . The computational solvent mapping algorithm FTMap was used to predict the most probable CB7993113-AHR PAS-B domain-binding position. This method places small molecular probes of various sizes and shapes on a dense grid around the protein, finds favorable positions using empirical energy functions, clusters the conformations, and ranks the clusters on the basis of the average energy. All ligands and crystallographic water molecules were removed prior to mapping, and the probes were initially distributed over the entire protein surface (including all cavities) without any assumptions about the binding site. The regions that bind multiple low energy probe clusters [consensus cluster (CC) sites], identified the most important ligand-binding sites. The hot spots were ranked in terms of the number of overlapping probe clusters contained. The consensus cluster with the highest number of probe clusters was ranked first as CC1 and nearby consensus clusters within 7 Å were also joined with CC1 to form the predicted ligandbinding site.
Only nonidentical residues and regions around the gaps were optimized and the predicted ligand-protein complex was then minimized using the CHARMM potential (Brooks et al., 1983) to avoid potential steric clashes. The FTMap algorithm (http://ftmap.bu.edu) (Brenke et al., 2009) 
In Vitro Protein Synthesis and Competitive-Binding Assay
Murine and human AHR proteins were synthesized from AHR expression constructs (pSportMAHR or pSportAHR2, respectively, gifts of Dr. C. Bradfield, University of Wisconsin, Madison, WI) (Burbach et al., 1992; Dolwick et al., 1993 ) using a TnT Quick Coupled reticulocyte lysate system (Promega). The ability of CB7993113 or CH223191 to compete with [ 3 H]TCDD (35 Ci/mmol; Chemsyn Science Laboratories, Lenexa, KS) for binding to human or mouse AHR was measured by velocity sedimentation on sucrose gradients in a vertical tube rotor as described earlier (Karchner et al., 2006) . Briefly, single TnT reactions (50 ml) were diluted 1:1 with MEEDMG buffer (25 mM MOPS, 1 mM EDTA, 5 mM EGTA, 0.02% NaN3, 1 mM DTT, 20 mM molybdate, 10% (v:v) glycerol, pH 7.5) and incubated overnight at 4°C with [ 3 H]TCDD (2 nM) 6 DMSO or competitor (10 mM final concentration, dissolved in DMSO). Incubations were applied to 10-to 30%-sucrose gradients and analyzed as described (Karchner et al., 2006 Human AHR-Driven Reporter Assay BP1 cells (2 Â 10 4 /well) were plated in 24-well plates and allowed to adhere overnight. Cells were cotransfected with 0.1 mg of the pGudluc reporter plasmid, 0.1 mg CMV green, and 0.5 mg of either pcDNA or an Ahrr expression plasmid using Lipofectamine 2000 (Life Technologies), as we previously described (Yang et al., 2008) . Cultures were incubated for 3 hours and then dosed with vehicle (DMSO, 0.1%), CH223191 (0.01-1 mM), or CB7993113 (1-20 mM). After 1 hour, the transfection medium was replaced, the cultures were redosed, and then incubated for 24 hours. Cells were harvested in Glo Lysis Buffer (Promega) and luciferase activity was determined with the Bright-Glo Luciferase System per the manufacturer's instructions (Promega). Luminescence and fluorescence values were determined using a Synergy 2 plate reader. To calculate "fold change from naïve" the luminescence value was divided by the fluorescence value for each sample.
Human Peroxisome Proliferator-Activated Receptor Gamma-and Cytomegalovirus-Driven Reporter Assays
Cos-7 cells were transiently transfected with vectors containing human peroxisome proliferator-activated receptor gamma (PPARg, PPARG1) (kindly provided by V. K. Chatterjee, University of Cambridge, Cambridge, UK) (Gurnell et al., 2000) and human RXRA (plasmid 8882; Addgene, Cambridge, MA) with PPRE Â3-TK-luc (plasmid 1015; Addgene) and cytomegalovirus (CMV)-eGFP-reporter constructs using Lipofectamine 2000 (Life Technologies). Transfected cultures were incubated for 3 hours. The medium was replaced with antibiotic-free DMEM with 5% fetal bovine serum and the cultures were incubated overnight. Cultures received no treatment (naïve) or were treated with vehicle (Vh; DMSO, 0.1%) or with rosiglitazone (1 mM) and Vh, CH223191 (10 mM), or CB7993113 (10 mM), and incubated for 24 hours. Cells were lysed in Glo Lysis Buffer (Promega). Lysates were transferred to a 96-well plate to which Bright Glo Reagent (Promega) was added. Luminescence and fluorescence were determined using a Synergy 2 plate reader. PPARg-specific luminescence was normalized to the GFP fluorescence in the same well. For the CMV-driven reporter assay, human mammary tumor cells (BP1) were transfected with CMV-driveneGFP-reporter plasmid (.80% transfection efficiency) and treated with CH223191 or CB7993113 as described above. GFP fluorescence was assayed 24 hours later. Constitutive CMV-reporter activity was calculated relative to levels seen in naïve cultures.
Mouse AHR Immunoblotting
H1G1.1c3 cells were plated at 2 Â 10 6 cells in T75 flasks and allowed to adhere overnight. Cells were treated with CB7993113 (10 mM), vehicle (DMSO, 0.1%), or left untreated for 1 hour, followed by DMBA (10 27 M) treatment for 30 minutes. Nuclear and cytoplasmic cell extracts were prepared using the Nuclear Extract Kit (Active Motif, Carlsbad, CA) per the manufacturer's instructions. Protein concentration was quantified using Protein Assay Reagent (Bio-Rad, Hercules, CA). Protein (30 mg) was resolved on 12% SDS-polyacrylamide gels and transferred to 0.2-mm nitrocellulose membranes (Bio-Rad). Membranes were probed with the following primary antibodies: mouse anti-AHR (Pierce, Rockford, IL), rabbit anti-Lamin-A/C (Cell Signaling Technologies, Danvers, MA), and mouse anti-a-tubulin (EMD Millipore, Billerica, MA). Immunoreactive bands were detected using horseradish peroxidase (HRP)-conjugated secondary antibodies [goat anti-rabbit (Bio-Rad), goat anti-mouse (Pierce)], and ECL substrate.
Human CYP1B1 mRNA Expression BP1 cells (3 Â 10 6 ) were plated in T225 flasks and allowed to adhere overnight. Cultures were dosed with CB7950998 (10 mM) or vehicle (DMSO, 0.1%) and incubated for 24 hours. mRNA was extracted using RNeasy Plus Mini Kit (Qiagen, Valencia, CA). cDNA was prepared from total RNA using the GoScript Reverse Transcription System (Promega), with a 1:1 mixture of random and oligo (dT) 15 primers. All real-time qPCR reactions were performed using the GoTaq RT-qPCR Master Mix System (Promega). Validated primers were purchased from Qiagen: human CYP1B1-QT00209496 and human RRN18S-QT00199367. Real-time qPCR reactions were performed using a 7900HT Fast Real-Time PCR instrument (Applied Biosystems, Carlsbad, CA): Hot-Start activation at 95°C for 2 minutes, 40 cycles of denaturation (95°C for 15 seconds), and annealing/extension (55°C for 60 seconds). Relative gene expression was determined using the Pfaffl method (Pfaffl, 2001 ) with the threshold value for RRN18S for normalization. The C q value from untreated cultures was used as the reference point.
Invasion and Migration Assays
For Matrigel assays, BP1 cells (3 Â 10 5 cells/well) were plated in sixwell plates and allowed to adhere overnight. Cells were pretreated with vehicle (DMSO), CH223191 (10 mM), CB7993113 (5 mM), or left untreated for 24 hours. Cells were harvested and prepared as a single cell suspension for addition to the Matrigel branching assay. Matrigel basement membrane matrix (BD Biosciences, Bedford, MA) was diluted to 6.3 mg/ml. Matrigel solution (200 ml) was added to a 24-well plate and solidified at 37°C for 30-45 minutes to form a base layer. Single-cell suspensions containing 2 Â 10 4 pretreated BP1 cells in 10 ml serum-free media were mixed with 190 ml of Matrigel containing 0.1% vehicle or 5-10 mM CB7993113. Vehicle or CB7993113 was also added to the Matrigel top layer and the layer allowed to solidify at 37°C for 30-45 minutes. Complete medium (0.5 ml) containing vehicle (DMSO, 0.1%) or CB7993113 (5 or 10 mM) was added on top of solidified Matrigel and was replaced with fresh dosing solution every other day. Colony morphology was captured using a Zeiss Axiovert 200 M microscope. Images were captured using a Nikon Coolpix4300 digital camera.
For "scratch-wound" assays , Hs578T or SUM149 cells (500,000 cells/well) were plated in six-well plates and allowed to grow until 100% confluent. Cultures were scratched with a pipette tip, left untreated, or treated with vehicle, 10 mM CH223191, or 10 mM CB7993113, and allowed to regrow for 48 hours. Cultures were photographed using a Nikon CoolPix 4300 attached to a Zeiss Telaval31 inverted microscope at 0, 24, and 48 hours.
In Vivo Studies
Male, 6-8 week old C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at Boston University. For pharmacokinetic studies, 13-week-old mice (four/group) were treated with 50 mg/kg CB7993113 by oral gavage or intraperitoneal injection. Serum was collected 4, 8, and 16 hours after treatment and from untreated mice. Serum samples were analyzed by liquid chromatography-tandem mass spectrometry for CB7993113 at Apredica/Cyprotex (Watertown, MA). For DMBAinduced bone marrow toxicity studies, mice (six per group) were injected intraperitoneally with vehicle (100 ml vegetable oil), CH223191 (50 mg/kg), or CB7993113 (50 mg/kg) 24 hours and 1 hour before dosing with 200 ml sesame oil or 50 mg/kg DMBA by oral gavage. Mice were euthanized 48 hours after DMBA treatment. Liver was snap frozen for mRNA analysis. Bone marrow was flushed from femurs and tibiae and red blood cells (RBCs) were removed using ACK Lysing Buffer (BioWhittaker, Lonza, Allendale, NJ).
For gene expression analyses, mRNA was extracted from liver tissues using the RNeasy Plus Mini Kit (Qiagen) and concentrated, if required, using the RNeasy MinElute Cleanup Kit (Qiagen). cDNA was prepared and real-time qPCR was carried out, as described above. Primer sequences for murine Cyp1a1 and murine Gapdh were previously described (Xu and Miller, 2004) and were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA). Relative gene expression was determined using the Pfaffl method (Pfaffl, 2001) , with the threshold value for Gapdh used for normalization. The C q value from untreated animals was used as the reference point.
For flow cytometry analyses, RBC-depleted bone marrow samples were treated with Fc-blocking solution (BD Biosciences, San Jose, CA) and suspended in phosphate-buffered saline (Life Technologies) supplemented with 2% fetal bovine serum (Gemini, West Sacramento, CA) for 15 minutes at 4°C. Samples were subsequently surface-stained with a cocktail of IgM-, CD24-, CD43-, and B220-specific antibodies, a cocktail of Gr-1-, CD3-, NK1.1-, CD11b-, and B220-specific antibodies, or their appropriate isotype-matched antibodies for 30 minutes at 4°C in the above staining buffer. All flow cytometry antibodies were obtained from BD Biosciences or eBiosciences (San Diego, CA). Samples were analyzed on a BD LSR II instrument. Post-acquisition analysis was performed using FlowJo analysis software (TreeStar).
Statistical Analysis
Statistical analyses were performed with GraphPad Prism (La Jolla, CA). Data are presented as means 6 S.E. where applicable. One-tailed Student's t tests and one-way analysis of variance with Dunnett, Tukey-Kramer, or Newman-Keuls post-hoc were used to determine significance.
Results
Virtual Screening and Generation of Focused Libraries. Development of modulators that can alter AHR function is of growing importance given the established role that the AHR plays in mediating toxic effects of environmental chemicals and the emerging role of the AHR in inflammatory diseases, autoimmunity, hematopoiesis, and cancer. To this end, known AHR-ligand structures and shape-based modeling were used to predict new AHR ligands and to generate targeted libraries of small molecules with substructures similar to those of known natural and anthropogenic AHR ligands. Noting the prevalence of flavonoid-like molecules in known AHR ligands, a generic substructure, 4-oxo-2-phenylchroman-3-yl methylcarbamate (Supplemental Fig. S2) , was selected as a basis to search for shape-and electrostatic-based similarities in commercial sets of compounds from two vendors, Enamine and ChemBridge, Inc.
Databases consisting of 445,418 and 731,288 small molecules from ChemBridge and Enamine, respectively, were scrutinized for three-dimensional conformers similar to the flavonoid substructure using the OMEGA algorithm. The three-dimensional conformer set generated from this analysis was then compared with generic flavonoid substructures by ROCS shape comparison. Subsequently, compounds that ranked highest in structural overlap from the ROCS comparison were subjected to an electrostatic analysis using EON electrostatic comparison and were reranked according to their electrostatic Tanimoto (ET) score. Focused libraries of the top 197 small-molecule hits from the Enamine and ChemBridge databases were generated (Supplemental Table S1 ) and tested for AHR modulating activity in vitro.
In Vitro Identification of Novel AHR Antagonists. A murine reporter-based bioassay (Nagy et al., 2002) was adapted for semiautomated, high-throughput screening of the aforementioned focused library for AHR agonists and antagonists. This assay utilizes the murine hepatoma cell line H1G1.1c3 that is stably transfected with an AHR-responsive EGFP reporter to measure AHR transcriptional activity. To assess AHR agonist activity, each experimental compound at 1 mM or 5 mM concentration was added alone to H1G1.1c3 cells. For AHRantagonist screening, each experimental compound was added immediately prior to addition of 10 27 M b-NF, a well-described
Identification of an AHR Antagonist AHR agonist. EGFP expression was assayed 24, 48, and 72 hours later.
Of the 197 compounds screened, 31 compounds exhibited agonist activity, as defined by a $25% increase in reporter activity at 1 and 5 mM and at all three time points when added alone to the reporter assay (data not shown). Four compounds demonstrated significant antagonist activity as defined by a $25% reduction in b-NF responses at 1 and 5 mM and at all three time points (Fig. 1, arrows) . The structures of the putative antagonist compounds and, for comparison, those of other previously described AHR antagonists, CH223191 (Kim et al., 2006) , StemRegenin (SR1) (Boitano et al., 2010) , GNF351 (Smith et al., 2011) , and 6, 29,49trimethoxyflavone (Zhao et al., 2010) are provided in Fig. 2 . Note the relative structural dissimilarity of CB7993113 when compared with most of the other "pure" AHR antagonists.
Several compounds (e.g., a-naphthoflavone, galangin) exhibit partial AHR agonism (Santostefano et al., 1993; Zhang et al., 2003; Dvorak et al., 2008) . Partial AHR agonists may appear to inhibit the AHR in bioassays since they compete with highefficacy ligands for AHR binding but cannot fully activate the receptor. None of the four putative AHR antagonists discovered in this screen induced AHR-driven reporter activity in the highthroughput assay, even at the highest concentration tested (10 mM) (data not shown and Figs. 3 and 4) , indicating that they are not partial agonists.
The potency and efficacy of the four discovered AHR antagonists were compared with CH223191 using the highthroughput H1G1.1c3 assay (Fig. 3) . At maximal concentrations, the four discovered AHR antagonists inhibited between 40 and 70% of the b-NF-induced EGFP signal, with CB7993113 exhibiting the greatest efficacy (Table 1) . IC 50 values ranged from 0.023 to 1.85 mM ( Table 1) . None of the compounds were toxic even at the highest dose tested, as defined by a $10% increase in dead cells after 48 hours of exposure. All of the compounds were within Lipinski's guidelines for drug-likeness (Lipinski et al., 2001 ). Interestingly, the low IC 50 (i.e., high potency) exhibited by T0515-7358 (0.02 mM) was not reflected in a significantly higher efficacy (68% inhibition) than the other discovered compounds. This is not an unusual finding since the potency, in part a function of ligand-receptor affinity, does not necessarily correlate directly with efficacy, a function of the biologic response to the ligand. This result further highlights differences between AHR antagonists.
Compounds CB7993113 and T0515 exhibited the greatest efficacy (maximum percent inhibition). As anticipated on the basis of calculated lipophilicity (c Log P) values, CB7993113 was qualitatively observed to be more soluble in phosphate-buffered saline than the other compounds and therefore was prioritized for further study.
In a separate series of experiments, head-to-head comparisons were made between CH223191 and lead compound CB7993113, using a prototypic, toxic AHR ligand, DMBA (Teague et al., 2010) , which also was used in in vivo bone marrow toxicity assays (see below). CB7993113 was slightly less potent than CH223191 as measured by reduction of DMBA-induced AHR reporter activity in H1G1.1C3 cells (IC 50 s 2.1 mM versus 0.7 mM, respectively; Fig. 4A ). However, CB7993113 was more effective than CH223191 at reducing DMBA-induced reporter activity under these conditions (46 versus 28% respectively). Again, neither CB7993113 nor CH223191 acted as a partial agonist at doses ranging from 1 nM to 10 mM (Fig. 4B ) and neither compound exhibited cytotoxicity as determined in an MTT assay (Fig. 4C) . Furthermore, neither compound affected reporter activity mediated by an unrelated nuclear receptor, PPARg, or reporter activity driven by a constitutive CMV promoter (Supplemental Fig. 3) . Collectively, these data indicate that at least one predicted new compound, CB7993113, specifically antagonizes murine AHR transcriptional activity, does not exhibit partial AHR agonist activity, and is not cytotoxic, even at relatively high concentrations.
To begin to assess whether CB7993113 is probably a competitive or allosteric inhibitor, titered concentrations of b-NF (10 28 to 10 25 M) or TCDD (10 213 to 10 29 M) and CB7993113 (10 27 to 10 25 M) were added to H1G1.1c3 cells and the percent induction of TCDD-induced, AHR-driven reporter activity assayed 24 hours later. If CB7993113 is an allosteric inhibitor, then little or no change in the potency (EC 50 ) of an AHR agonist Vendor catalog numbers, chemical names, molecular weights, and Log P (partition coefficient) values are presented. The c Log P values were determined using Pipeline Pilot (Accelrys). Maximum percent inhibition values were determined from data presented in Fig. 3 using 50 mM concentrations of the respective compounds and assaying on day 3. IC 50 values were determined from the dose-response curves generated in Fig. 3 using GraphPad Prism. Identification of an AHR Antagonist should be seen after addition of titered concentrations of the inhibitor. In contrast, if CB7993113 is a competitive inhibitor, then agonist EC 50 should increase as increasing concentrations of inhibitor are added. Indeed, the b-NF and TCDD titration curves shifted to the right (increasing EC 50 ) as the concentration of CB7993113 was increased ( Supplemental Fig. 4 ). These data are consistent with competitive inhibition. A competitive AHR antagonist would be expected to bind directly to the AHR and, at a minimum, block agonist-induced nuclear translocation. Therefore, the capacity of CB7993113 to directly bind to in vitro translated murine AHR protein was determined in a [ (Fig. 5A) .
Several AHR ligands, including at least one AHR competitive antagonist (Boitano et al., 2010) , exhibit species-specific AHR-binding characteristics. Therefore, the ability of CB7993113 to bind human AHR also was assessed using in vitro translated human AHR. The ability of CB7993113 to inhibit the binding of [ 3 H]TCDD to human AHR was similar to that seen with murine AHR, whereas CH223191 was slightly more effective as an inhibitor of [ 3 H]TCDD binding to human AHR compared with mouse AHR (Fig. 5B) .
As would be expected from a competitive antagonist, 10 mM CB7993113 completely prevented DMBA-induced AHR nuclear translocation (Fig. 5C ). Partial inhibition of AHR nuclear translocation was seen in two experiments with as little as 1 mM CB7993113 (data not shown). Consistent with our findings with the AHR-driven reporter assay, 10 mM CB7993113 alone did not induce nuclear translocation of the AHR protein and thus was not acting as a partial AHR agonist (Fig. 5C ). These data collectively indicate that CB7993113 is probably a competitive AHR antagonist and that it blocks AHR nuclear translocation and, thereby, transcriptional activity. Homology Modeling of CB7993113-AHR Binding. To begin to visualize the orientation of this putative competitive inhibitor in the binding pocket of the human AHR PAS-B domain, the X-ray structure of the HIF-2a PAS-B domain, cocrystallized with the small antagonist N-(3-chloro-5-fluorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine (4GH1) (Scheuermann et al., 2013) was selected as the template for model building. The recent crystal structure of the mouse PAS1 (PAS-A) domain (PDB ID 4M4X) (Wu et al., 2013) indicates that the human AHR PAS-B domain begins after residue Q273, and hence AHR residues 287-390 were aligned with HIF-2a residues 244-348 (Supplemental Fig. 5 ). The two sequences have 27% identity and 50% similarity in this range. Although this level of sequence identity is relatively low for homology modeling, the identical residues distribute almost equidistantly along the domain with only a two-percent (three amino acids) gap. This type of distribution makes it very probable that the backbones of the two proteins are very similar. Indeed, structures are available for a number of PAS domains with similar level of sequence identity and good three-dimensional overlap.
The MODELER mapping results were used in two different ways to approximate CB7993113 docking. First, a box with 4-Å padding was created around the predicted binding site. The docking was carried out restricting consideration to this box and using the standard settings of AutoDock Vina 1.1.0 (Scripps Institute) (Trott and Olson, 2010) . The 10 lowest energy binding poses were retained for each ligand. Second, for the selection of the most probable pose, the AutoDock Vina energy score and the atom densities calculated from the mapping results were included in the calculus. Probe density was defined at each point binding site as the total number of probe atoms within a 1.25-Å radius. We considered each retained ligand pose and summed the atomic densities for all heavy atoms, resulting in a measure of overlap between the pose and the probe density. The poses with low energy scores were ranked on the basis of this overlap measure, and the pose with the best overlap was selected (Kozakov et al., 2011) . Figure 6A shows the template, the PAS-B domain of HIF-2a, with the bound antagonist. The backbone of the homology model of the human AHR is very similar (Fig. 6B ). There is no template for the AHR loop 371-376 and thus it was constructed by MODELER. (Note that this loop is far from the binding site and its exact structure is not important for this model.) Figure 6B also shows the probe clusters obtained by the mapping program FTMap and indicating the energetically most important regions of the binding site. We note that the sequence differences between HIF-2a and AHR results in a larger binding cavity and greater hydrophobicity of the AHR. Consequently, the site can accommodate CB7993113 in a number of conformations and the 10 lowest energy docked poses of Identification of an AHR Antagonist CB7993113 show substantial variation. Figure 6C shows one of the lowest energy structures (pose 2 from AutoDock Vina) that also overlaps well with the binding hot spots. The hydrophobic part of the chromen-3 moiety of the ligand is surrounded by the side chains of F295, M340, and A367, whereas H291 and Q383 donate hydrogen bonds to the more polar regions of CB7993113. For better visibility, Fig. 6D shows only a few of the side chains that are within 5 Å of the ligand. Interestingly, the differences in the amino acids shown in the AHR yield less bulky side chains, and thus increase the size of the ligand-binding cavity relative to HIF-2a.
CB7993113-Mediated Inhibition of AHR-Dependent Biologic Responses. AHR expression and activation in the absence of environmental ligands is associated with several human cancers, including breast cancer (Brooks and Eltom, 2011; Opitz et al., 2011; Schlezinger et al., 2006) . It is presumed that this basal activity is mediated by endogenous AHR ligands. Therefore, it was predicted that CB7993113, like AHR repressor protein (Yang et al., 2008) , would lower baseline levels of AHRdriven reporter activity and endogenous target gene expression in human breast cancer cells. Malignant triple-negative BP1 cells were used for these studies since we had previously established relatively high baseline levels of AHR (reporter) activity and AHR-dependent enforcement of high CYP1B1 levels in this invasive cell line (Yang et al., 2008) . BP1 cells were transiently transfected with the pGudLuc AHR-driven reporter plasmid. As previously reported (Yang et al., 2008) , cotransfection with a plasmid carrying the AHR repressor gene (Ahrr) significantly reduced baseline pGudLuc reporter activity (Fig. 7A) . Similarly, treatment of pGudLuc-transfected cells with CB7993113 significantly decreased baseline AHR activity at concentrations as low as 5 mM (Fig. 7A) . CB7993113 also tended to decrease endogenous CYP1B1 levels in this shortterm experiment, although statistical significance was only reached at a concentration of 20 mM (Fig. 7B) .
Our laboratory (Trombino et al., 2000; Schlezinger et al., 2006) and others (Brooks and Eltom, 2011; Opitz et al., 2011) have postulated that AHR hyperexpression and activity facilitate malignant transformation. It would then be predicted that AHR antagonists would reverse at least some component of the malignant phenotype. The growth of immortalized cells in irregular, branching colonies in Matrigel is widely seen as a marker for invasiveness (Hughes et al., 2008) . Indeed, we have demonstrated that inhibition of AHR activity with AHRR or AHR knockdown with AHR-specific small-interfering RNA blocks the formation of branching colonies in human breast cancer cell lines (S. Narasimhan et al., manuscript in preparation). Therefore, the ability of CB7993113 to alter the morphology of BP1 cell colonies in Matrigel was assessed. Untreated or vehicle-treated BP1 cell colonies exhibited the branched, irregular morphology typical of invasive cells as early as day 3 of culture ( Fig. 7C) . However, treatment with either 10 mM CH223191 or 5 mM CB7993113 clearly reduced the size of the colonies and their degree of branching. Higher magnification images revealed that CB7993113 tended to decrease formation of invasive cell processes (Fig. 7D) .
It is possible that the morphologic changes seen in the presence of CB7993113 are, in part, a function of altered cell growth or toxicity. However, [ 3 H]thymidine incorporation experiments in two-dimensional BP1 cultures failed to demonstrate a significant change in cell growth or viability (more than five experiments, data not shown). Furthermore, the number of viable cells recovered from 7-to 10-day-old three-dimensional Matrigel cultures, as determined by Trypan blue exclusion and visual inspection or by propidium iodide exclusion and flow cytometry, was not affected by CB7993113 treatment (three experiments, data not shown). Therefore, the changes in morphology observed with CB7993113 were not attributable to decreased cell growth or increased toxicity.
To assess whether CB7993113 inhibits another marker of tumor invasiveness, i.e., migration across a "scratch wound," and to extend studies to two other cell lines, confluent cultures of AHR high (Yang et al., 2008) Hs578T (triple-negative) and SUM149 (inflammatory breast cancer-derived) cells were "wounded" in a scratch assay , treated with vehicle (DMSO), 10 mM CH223191, or 10 mM CB7993113, and photographed 24 and 48 hours later. Naïve or vehicletreated Hs578T and SUM149 cultures closed the scratch wound completely by approximately 56 and 72 hours, respectively (not shown). Whereas vehicle had no effect on the rate of wound closure, treatment with either CH223191 or CB7993113 consistently inhibited wound closure in both cell lines at 24 and 48 hours (Fig. 8) . Cells were harvested 24 hours later and luciferase activity assayed. Luciferase (AHR-reporter) activity was first normalized to the GFP signal to control for transfection efficiency and then normalized to the luciferase signal obtained from untreated cells. Data are expressed as means 6 S.E. obtained from three independent experiments. (***P , 0.001 compared with vehicle groups; one-way analysis of variance (ANOVA) with Dunnett's post-test.) (B) BP1 cells were treated with vehicle (DMSO) or 1-20 mM CB7993113 for 24 hours. mRNA was extracted and analyzed by qPCR for CYP1B1 expression normalized to 18sRNA expression. qPCR was performed in duplicate. Data are expressed as means 6 S.E. from three to five independent experiments. (*P , 0.05, compared with vehicle groups, ANOVA with Dunnett's post-test.) (C) BP1 cells were treated with vehicle (0.1% DMSO), 10 mM CH223191, 5 mM CB7993113, or left untreated for 24 hours. Cells were harvested, counted, and plated in Matrigel. Representative images from three independent experiments were taken on days 3 and 5. (D) BP1 cells were treated as in (C) with vehicle or CB7993113 (10 mM). High magnification images were captured on day 5 to illustrate cell morphology. CB7993113-treated cells extracted from Matrigels were ∼95% viable. No significant differences in the numbers of cells in cultures after extraction from three-dimensional cultures were seen.
Identification of an AHR Antagonist
Results in both the Matrigel and scratch-wound assays are consistent with a role for the AHR in breast cancer cell invasiveness and suggest the use of AHR antagonists to pharmacologically alter constitutive AHR activity in and potential invasiveness of cancer cells.
In Vivo Efficacy of the AHR Antagonist CB7993113. Drugs to be used as therapeutics must exhibit several properties in vivo, including sufficient solubility, absorption, stability, and accumulation in target organs at biologically relevant concentrations. Although in silico computation predicted that CB7993113 would satisfy these criteria, in vivo studies were required to confirm this prediction. In the absence of an animal model system that faithfully and consistently recapitulates breast cancer cell invasion in humans, we chose to evaluate CB7993113 in vivo efficacy using surrogate endpoints of bioactivity, i.e., the ability to block acute AHR-mediated CYP1A1 induction in liver and AHR-regulated bone marrow toxicity (Teague et al., 2010; N'jai et al., 2011) .
In pharmacokinetics experiments, 50 mg/kg CB7993113 was readily absorbed in vivo following either intraperitoneal or oral administration. Thus, 823 6 263 nM and 395 6 162 nM CB7993113 were detected in sera 1 hour after intraperitoneal injection or oral gavage, respectively. The compound exhibited a serum half-life of 4.0 hours (data not shown). Therefore, a dose of 50 mg/kg was used for further in vivo studies.
As expected from in vitro studies, intraperitoneal injection of 50 mg/kg CB7993113 did not induce CYP1A1 mRNA expression in liver as assessed by real-time qPCR (Fig. 9A) , indicating that neither this compound nor its metabolites are partial AHR agonists in vivo. In contrast, an equal concentration of DMBA induced a significant, 200-to 400-fold, increase in CYP1A1 at this 48-hour time point. DMBA-induced CYP1A1 induction was inhibited by both CH223191 and CB7993113, although inhibition of DMBA-induced CYP1A1 expression was less consistent with CH223191 than with CB7993113.
In previous studies, we and others demonstrated that DMBA exposure induces a dramatic loss of bone marrow pro-and pre-B cells and other hematopoietic cell types, probably through induction of apoptosis (Mann et al., 1999; Teague et al., 2010; N'jai A et al., 2011) . To determine if CB7993113 could reach sufficient concentrations in situ to block this AHR-dependent bone marrow toxicity, C57Bl/6 mice were treated with vehicle, 50 mg/kg CB7993113, or, as a positive control, 50 mg/kg CH223191, by intraperitoneal injection 24 hours and 1 hour before oral gavage with 50 mg/kg DMBA. Mice were euthanized 48 hours later, bone marrow cells were collected, and hematopoietic cells were phenotyped by flow cytometry. As expected from in vitro studies in which CB7993113 failed to exhibit toxicity, it also failed to affect the number of bone marrow cells recovered 48 hours after intraperitoneal injection (Fig. 9B) . In contrast, a significant reduction in the total number of bone marrow cells was observed after DMBA treatment. This acute bone marrow cell ablation was inhibited by treatment with either CB7993113 or CH223191 (Fig. 9B) .
Phenotypes of bone marrow subpopulations were analyzed to determine which hematopoietic cell subsets were affected and to determine if CB7993113 could protect all subsets from DMBA-induced toxicity. No significant changes were seen in the resident bone marrow T cell (CD3 1 ) or natural killer cell (NK1.1 1 ) populations following treatment with DMBA, CH223191, CB7993113, or combinations of DMBA with either antagonist (data not shown). In contrast, DMBA treatment significantly reduced the number of pre/pro-B cells (IgM
1 /HSA 1 ) (Hardy and Hayakawa, 2001) , and neutrophils (CD11b hi /GR-1 hi ) (Sukhumavasi et al., 2007) (Fig. 9 , C-E). Notably, pretreatment of mice with either antagonist significantly inhibited DMBA-induced toxicity in all three cell populations. These data confirm the ability of a prototypic AHR ligand to adversely affect bone marrow cells destined to contribute to the adaptive immune response, i.e., pre/pro-and pro-B cells, and to the innate immune response, i.e., neutrophils. Importantly, CB7993113 prevented a significant DMBA-induced loss of these three bone marrow cell subsets. These data demonstrate the achievement of physiologically relevant doses of CB7993113 in vivo, and suggest that this nontoxic antagonist could be used to block AHR activity either induced acutely by environmental ligands or chronically during a variety of pathologic conditions. 
Discussion
The AHR has been recognized for many years as a key regulator of environmental chemical toxicity and carcinogenicity. Indeed, it mediates the biologic effects of some of the most potent toxicants known, including TCDD. Of equal concern, from an environmental point of view, is the ability of the AHR to bind and respond to a variety of structurally disparate chemicals, including planar polychlorinated biphenyls, dioxins, polycyclic aromatic hydrocarbons, plant-derived flavonoids and tryptophan-derived metabolites. Whereas this receptor's promiscuity and the resulting pathologic consequences are reason enough to study AHR signaling pathways, in the end, the AHR's role in regulating normal and pathologic biologic activities in the absence of environmental ligands may prove to be the more compelling story. In this vein, the AHR promotes the production of IL-17-secreting T cells critical to inflammationbased diseases and some forms of autoimmunity (Quintana et al., 2012) , and affects production of regulatory T cells that oppose inflammatory and autoimmune responses (Apetoh et al., 2010; Gandhi et al., 2010) . AHR signaling also plays a key role in development of gut-associated leukocytes that mediate both the innate and adaptive immune responses required to prevent microbial infiltration and the resulting inflammatory colitis (Kiss et al., 2011; Li et al., 2011) . In various model systems, the AHR also contributes to hematopoietic stem cell development (Boitano et al., 2010; Casado et al., 2010; Smith et al., 2013) . Consequently, the ability to regulate AHR activity may be important for treatment of hematologic diseases. Accordingly, studies have shown that AHR modulation attenuates disease in models of multiple sclerosis and type 1 diabetes (Quintana et al., 2008; Kerkvliet et al., 2009) . Perhaps most strikingly, AHR modulators have a promising application in stem cell biology as demonstrated by the expansion of human CD34 1 progenitor cells from cord blood by culture with the purinederived AHR antagonist SR1 (Boitano et al., 2010) and the development of bipotential hematopoietic stem cells, megakaryocytes, and erythroid cells from AHR-activated, induced pluripotent stem cells (Smith et al., 2013) .
Here, we present a combined in silico and high-throughput in vitro screening platform for the identification of AHR modulators, both agonists and antagonists. Several bioflavonoids, among other phytochemicals, have been identified as AHR ligands. The activity of most of these previously identified compounds ranges from weakly agonistic to weakly antagonistic (Lu et al., 1996; Zhang et al., 2003) . However, select compounds induce significant AHR-dependent biologic effects, including several flavones, such as b-NF, used here as a prototypic AHR agonist. Therefore, we chose a generic substituted flavone backbone as our pharmacophore upon which to perform shape and electrostatic comparisons. In a novel approach to generating a template molecule that could be used to screen over a million small molecules in silico, the flavone-based model pharmacophore was expanded into a three-dimensional conformer database and the molecular shapes were compared with a similar database containing conformers of 1,176,756 commercially available, druglike molecules. A focused library of 197 compounds was selected on the basis of three-dimensional electrostatic similarities.
The validity of this approach was confirmed by a relatively high "hit" rate. Of the 197 compounds assayed in the bioassay, Identification of an AHR Antagonist 31 consistently induced AHR reporter activity with 27 of those exhibiting an EC 50 of ,10 mM. Four compounds exhibited AHR antagonist activity, all with IC 50 s ,5 mM. This represents a hit rate for probable AHR ligands of 17.8%. Cell-free AHR binding studies performed on one antagonist (CB7993113, Fig. 5 ) and one agonist (data not shown) confirmed that each molecule was in fact an AHR ligand. Since both AHR agonists and antagonists may be useful in various therapeutic settings, this new approach to rapidly screening large libraries in silico for AHR ligands has great utility. Our AHR ligand screen identified a disproportionate number of agonists. This result is consistent with the literature in which identification of AHR agonists is far more common than the identification of pure antagonists, i.e., competitive AHR antagonists that do not exhibit partial agonism at higher doses. To date, relatively few "pure" AHR antagonists have been discovered. These include CH223191 (Kim et al., 2006) , 6,29,49-trimethoxyflavone (TMF) (Murray IA et al., 2009 ), SR1 (Boitano et al., 2010) , and GNF351 (Smith et al., 2011) . Identification of additional AHR antagonists, such as CB7993113, is important because each antagonist appears to exhibit unique properties in terms of affinity for AHRs from different species, "ligand selectivity," or ability to block AHR response elementdependent signaling (Smith et al., 2011) . For example, SR1 is a potent antagonist of the human AHR but has little or no effect on ligand binding to murine AHR. CH223191 exhibits ligand-selective inhibition, e.g., a propensity to block halogenated hydrocarbon-induced but not flavone-induced AHR activation (Zhao et al., 2010) . In contrast, CB7993113 appears to be a more generally applicable AHR antagonist in that it inhibits both human and murine AHR, blocks DMBA-, TCDD-, flavone (b-NF)-, and tryptophan metabolite (e.g., FICZ; data not shown)-induced AHR activity and reduces baseline AHR activity (e.g., baseline pGudLuc activity). It shows no agonist activity either in vitro at doses at least as high as 20 mM or in vivo at doses at least up to 50 mg/kg. Given the number and diversity of possible therapeutic applications for AHR antagonists, including but probably not limited to human hematopoietic stem cell expansion (Boitano et al., 2010) , T-cell expansion (Carlin et al., 2013) , inhibition of inflammatory Th 17 development (Veldhoen et al., 2009) , reduction in regulatory T-cell development (Apetoh et al., 2010) , expansion of erythroid and megakaryocyte lineage cells (Smith et al., 2013) , and inhibition of breast cancer cell invasion (Figs. 7 and 8) , identification of new, nontoxic AHR antagonists is of considerable import. Furthermore, expanding the database of AHR antagonists, which tend to be dissimilar in structure, will facilitate the definition of critical structural characteristics that confer the ability to inhibit, as opposed to induce, AHR activity. Again, this knowledge is critical to the rational design of more potent, nontoxic, pure AHR antagonists for therapeutic use.
Paramount to the identification of a novel antagonist is the confirmation of its drug-likeness and lack of toxicity. In our in vitro screen, compounds exhibiting any level of toxicity in murine H1G1 hepatoma cells were discarded. CB7993113 exhibited no toxicity when added at concentrations at least up to 20 mM to several human cells including HepG2 hepatoma cells, BP1, D3, Hs578T, or MDA-MB-231 breast cancer cells, and primary human-induced pluripotent stem cells (data not shown). Furthermore, CB7993113 is predicted to conform to Lipinski's rules and thereby is expected to demonstrate oral bioavailability. Pharmacokinetics studies demonstrating significant serum bioavailability after either oral or intraperitoneal administration were consistent with this conclusion. Most importantly, CB7993113 effectively blocked acute, 50 mg/kg DMBA-induced hepatic CYP1A1 induction and bone marrow toxicity in vivo, demonstrating not only sufficient drug absorption but adequate tissue distribution and persistence for inhibiting a strong AHR-dependent (Mann et al., 1999; N'jai A et al., 2011) biologic signal.
Finally, pure AHR antagonists like CB7993113 may be useful as cancer therapeutics. Earlier studies implicated the AHR in the control of important cell functions dysregulated during malignant transformation, including cell growth and cell migration (Dietrich and Kaina, 2010) . A more recent, high-profile study demonstrated that AHR, constitutively activated by an endogenous ligand, drives human glioblastoma invasion (Opitz et al., 2011) . Similarly, accumulating evidence suggests that hyper-expressed, "constitutively active" AHR plays a role in the malignant transformation of breast epithelial cells Brooks and Eltom, 2011; Goode et al., 2013) , in the expression of epithelial-tomesenchymal transition markers (Schlezinger et al., 2006; Shin et al., 2006) , and, most recently, in breast cancer stem cell homeostasis (Dubrovska et al., 2012; Zhao et al., 2012 
